← All trials
NCT00062439
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2003
- Primary completion
- Dec 1, 2010
- Completion date
- Dec 1, 2010
- First posted
- —
- Last posted
- —
- Enrollment
- 46
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Southwest Oncology GroupLead sponsor
- Mayo ClinicStudy chair
- Providence HospitalStudy chair
- University of WisconsinStudy chair
- University of OttawaStudy chair
- National Cancer Institute (NCI)Collaborator
- Eastern Cooperative Oncology GroupCollaborator
- North Central Cancer Treatment GroupCollaborator
- Canadian Cancer Trials GroupCollaborator
- American College of SurgeonsCollaborator
- Cornell UniversityStudy chair
- Washington University in St. LouisStudy chair
- Cancer and Leukemia Group B (CALGB)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.